These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31454632)

  • 1. Correlation between immunohistochemistry and RICTOR fluorescence in situ hybridization amplification in small cell lung carcinoma.
    Krencz I; Sebestyen A; Papay J; Lou Y; Lutz GF; Majewicz TL; Khoor A
    Hum Pathol; 2019 Nov; 93():74-80. PubMed ID: 31454632
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Krencz I; Sztankovics D; Sebestyén A; Pápay J; Dankó T; Moldvai D; Lutz E; Khoor A
    Pathol Oncol Res; 2024; 30():1611593. PubMed ID: 38706776
    [No Abstract]   [Full Text] [Related]  

  • 3. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.
    Kim ST; Kim SY; Klempner SJ; Yoon J; Kim N; Ahn S; Bang H; Kim KM; Park W; Park SH; Park JO; Park YS; Lim HY; Lee SH; Park K; Kang WK; Lee J
    Ann Oncol; 2017 Mar; 28(3):547-554. PubMed ID: 28028034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between RICTOR overexpression and amplification in advanced solid tumors.
    Bang H; Ahn S; Ji Kim E; Kim ST; Park HY; Lee J; Kim KM
    Pathol Res Pract; 2020 Jan; 216(1):152734. PubMed ID: 31740232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR.
    Sakre N; Wildey G; Behtaj M; Kresak A; Yang M; Fu P; Dowlati A
    Oncotarget; 2017 Jan; 8(4):5992-6002. PubMed ID: 27863413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer.
    Zhang L; Yu H; Badzio A; Boyle TA; Schildhaus HU; Lu X; Dziadziuszko R; Jassem J; Varella-Garcia M; Heasley LE; Kowalewski AA; Ellison K; Chen G; Zhou C; Hirsch FR
    J Thorac Oncol; 2015 Jul; 10(7):1083-90. PubMed ID: 26020126
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Kim LC; Rhee CH; Chen J
    Mol Cancer Res; 2020 Nov; 18(11):1675-1684. PubMed ID: 32801163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myc protein expression correlates with MYC amplification in small-cell lung carcinoma.
    Hwang DH; Sun H; Rodig SJ; Hornick JL; Sholl LM
    Histopathology; 2015 Jul; 67(1):81-9. PubMed ID: 25407018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
    Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
    Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex.
    Gkountakos A; Pilotto S; Mafficini A; Vicentini C; Simbolo M; Milella M; Tortora G; Scarpa A; Bria E; Corbo V
    Carcinogenesis; 2018 Jul; 39(8):971-980. PubMed ID: 29955840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR hyperactivity and
    Sztankovics D; Moldvai D; Petővári G; Dankó T; Szalai F; Miyaura R; Varga V; Nagy N; Papp G; Pápay J; Krencz I; Sebestyén A
    Pathol Oncol Res; 2024; 30():1611643. PubMed ID: 38515456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.
    Cheng H; Zou Y; Ross JS; Wang K; Liu X; Halmos B; Ali SM; Liu H; Verma A; Montagna C; Chachoua A; Goel S; Schwartz EL; Zhu C; Shan J; Yu Y; Gritsman K; Yelensky R; Lipson D; Otto G; Hawryluk M; Stephens PJ; Miller VA; Piperdi B; Perez-Soler R
    Cancer Discov; 2015 Dec; 5(12):1262-70. PubMed ID: 26370156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH.
    Yi ES; Boland JM; Maleszewski JJ; Roden AC; Oliveira AM; Aubry MC; Erickson-Johnson MR; Caron BL; Li Y; Tang H; Stoddard S; Wampfler J; Kulig K; Yang P
    J Thorac Oncol; 2011 Mar; 6(3):459-65. PubMed ID: 21278610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast growth factor receptor 1 gene amplification and protein expression in human lung cancer.
    Elakad O; Lois AM; Schmitz K; Yao S; Hugo S; Lukat L; Hinterthaner M; Danner BC; von Hammerstein-Equord A; Reuter-Jessen K; Schildhaus HU; Ströbel P; Bohnenberger H
    Cancer Med; 2020 May; 9(10):3574-3583. PubMed ID: 32207251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of mTORC2/RICTOR Impairs Melanoma Hepatic Metastasis.
    Schmidt KM; Dietrich P; Hackl C; Guenzle J; Bronsert P; Wagner C; Fichtner-Feigl S; Schlitt HJ; Geissler EK; Hellerbrand C; Lang SA
    Neoplasia; 2018 Dec; 20(12):1198-1208. PubMed ID: 30404068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of mTORC1/2-related proteins in primary and brain metastatic lung adenocarcinoma.
    Krencz I; Sebestyén A; Fábián K; Márk Á; Moldvay J; Khoor A; Kopper L; Pápay J
    Hum Pathol; 2017 Apr; 62():66-73. PubMed ID: 28025080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYCL1 Amplification and Expression of L-Myc and c-Myc in Surgically Resected Small-Cell Lung Carcinoma.
    Qin J; Xie F; Li C; Han N; Lu H
    Pathol Oncol Res; 2021; 27():1609775. PubMed ID: 34257619
    [No Abstract]   [Full Text] [Related]  

  • 18. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
    Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
    Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization.
    Wang W; Tang Y; Li J; Jiang L; Jiang Y; Su X
    Cancer Cytopathol; 2015 Feb; 123(2):117-22. PubMed ID: 25529354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
    Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
    PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.